Hyper Hypo Coagulability Assessment Photonic Integrated Chip based Point of Care
DAS Photonics (http://www.dasphotonics.com/) is a young SME company with about 37 employees and 3M€ total income in 2014. Since 2008 the company works in the field of nanophotonic biosensors, field where we propose the following o...
ver más
DAS PHOTONICS
La sociedad desarrollara sus actividades en el sector de las telecomunicaciones terrestres y espaciales, y tendra por objeto: a) el desarrol...
TRL
4-5
| 2M€
Fecha límite participación
Sin fecha límite de participación.
Financiación
concedida
El organismo H2020 notifico la concesión del proyecto
el día 2015-12-31
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PHOCNOSIS
Advanced nanophotonic point of care analysis device for fast...
4M€
Cerrado
CPP2021-009001
Desarrollo de un nuevo sistema fotónico para medidas de bioq...
197K€
Cerrado
PLEC2021-007727
Nanobiosensor multiplexado para el diagnóstico instantáneo y...
317K€
Cerrado
PTQ-15-07590
Desarrollo de una plataforma microfluídica para la detección...
84K€
Cerrado
PTQ-11-04708
Biosensores de nanotubos de carbono: detección del marcador...
92K€
Cerrado
PTQ-13-06305
Desarrollo de nuevos productos a base de microfluídica para...
100K€
Cerrado
Información proyecto C-POC
Duración del proyecto: 6 meses
Fecha Inicio: 2015-06-08
Fecha Fin: 2015-12-31
Líder del proyecto
DAS PHOTONICS
La sociedad desarrollara sus actividades en el sector de las telecomunicaciones terrestres y espaciales, y tendra por objeto: a) el desarrol...
TRL
4-5
| 2M€
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
DAS Photonics (http://www.dasphotonics.com/) is a young SME company with about 37 employees and 3M€ total income in 2014. Since 2008 the company works in the field of nanophotonic biosensors, field where we propose the following opportunity: Bleeding and thrombosis kill together more people than any other causes. The coagulation system, through the formation of thrombin is pivotal in these pathologies.
Therefore, the main objective of the overall innovation project is to develop, validate, and commercialise a new diagnostic tool (C-POC) based on the assessment of thrombin generation and simultaneously measurement of several biomarkers of hyper/hypo coagulability using a Photonic Integrated Chip (PIC). The thrombin generation assay is completed with two different sets of measurements, natural coagulation/anticoagulation factor assays and measurement of antiThrombin/antiFactor Xa drug levels. Consequently, a common test for anticoagulants monitoring including heparins and direct oral anticoagulants will be available. PIC based solution will provide an accurate diagnostic and/or patient evaluation with capacity for cost-effective, high sample throughput screening and point-of-care diagnosis. The proposed approach will reduce the occurrence of clinical events in stroke and systemic embolism providing gains in survival and quality of life. The incremental cost-effectiveness ratio is about a 20% per quality-adjusted life year gained when compared to current prescribing pattern. As a consequence, the social costs will be also reduced by providing extensively the C-POC solution to the First Point of Healthcare reducing in this way the risk of both thrombotic events and haemorrhages.